Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Pancreatic Neoplasms 3 Carcinoma, Pancreatic Ductal 2 Stomach Neoplasms 1 Recurrence 1 Pancreatic Adenocarcinoma 1 Neoplasms 1 Neoplasm Metastasis 1 Metastatic Pancreatic Adenocarcinoma 1 Cholangiocarcinoma 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1 Adenocarcinoma 1

Interventions

Dexamethasone 43 Cyclophosphamide 38 fludarabine phosphate 27 Cytarabine 26 Rituximab 24 Methotrexate 21 Lenalidomide 21 Bortezomib 21 Calcium Dobesilate 20 fludarabine 19 Peripheral Blood Stem Cell Transplantation 19 Whole-Body Irradiation 16 Mycophenolic Acid 16 pembrolizumab 15 Gemcitabine 15 Etoposide 15 pomalidomide 14 Melphalan 14 Vincristine 13 Filgrastim 13 Busulfan 13 Tacrolimus 12 Cyclosporine 12 Carboplatin 12 Paclitaxel 11 carfilzomib 10 durvalumab 9 Doxorubicin 9 Cetuximab 9 Brentuximab Vedotin 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Recurrence × PEGPH20 × Clear all

NCT02346370 2019-02-08

PRIMAL

Halozyme Therapeutics

Phase 1 Terminated

16 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡